On April 16, 2025, Aerovate Therapeutics' stockholders approved several proposals related to its merger with Jade Biosciences, including a reverse stock split of 1-for-35 and an increase in authorized shares from 150 million to 300 million. A cash dividend of $69.6 million, approximately $2.40 per share, will be paid to stockholders on April 25, 2025, prior to the merger completion.